Georg Arnold Bjarnason
Impact in
- Pulmonary and Respiratory Medicine top 0.1%
- Renal cell carcinoma treatment
- Cancer Research top 0.5%
- Cancer Genomics and Diagnostics
- Cancer, Hypoxia, and Metabolism
Papers in
-
- Renal cell carcinoma treatment 125
- Oncology 39
- Pancreatic and Hepatic Oncology Research 12
- Cancer Treatment and Pharmacology 6
- Colorectal Cancer Treatments and Studies 6
- Co-authors
- Christina R. Lee (2 shared papers)Robert S. Kerbel (2 shared papers)John M.L. Ebos (1 shared paper)James G. Christensen (1 shared paper)William Cruz‐Muñoz (1 shared paper)Frede N. Donskov (39 shared papers)Richard C. Jordan (7 shared papers)Toni K. Choueiri (37 shared papers)
- Journals
- Journal of Clinical Oncology (16 papers)Clinical Genitourinary Cancer (12 papers)Annals of Oncology (11 papers)European Urology (11 papers)European Journal of Cancer (6 papers)
- Partner nations
- CanadaUnited StatesDenmark
In The Last Decade
Georg Arnold Bjarnason
204 papers receiving 16.1k citations
Georg Arnold Bjarnason's Hit Papers
Peers
Comparison fields: 5 of 138
- Pulmonary and Respiratory Medicine 8.6k
- Cancer Research 3.6k
- Endocrine and Autonomic Systems 1.4k
- Oncology 3.6k
- Aging 191
Countries citing papers authored by Georg Arnold Bjarnason
This map shows the geographic impact of Georg Arnold Bjarnason's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Georg Arnold Bjarnason with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Georg Arnold Bjarnason more than expected).
Fields of papers citing papers by Georg Arnold Bjarnason
This network shows the impact of papers produced by Georg Arnold Bjarnason. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Georg Arnold Bjarnason. The network helps show where Georg Arnold Bjarnason may publish in the future.
Co-authors
The 25 scholars most cited alongside Georg Arnold Bjarnason, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 214 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma Hit paper breakdown → | 2009 | 1843 |
| 2 | Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis Hit paper breakdown → | 2009 | 1489 |
| 3 | Cabozantinib versus Everolimus in Advanced Renal-Cell Carcinoma Hit paper breakdown → | 2015 | 1004 |
| 4 | External validation and comparison with other models of the International Metastatic Renal-Cell Carcinoma Database Consortium prognostic model: a population-based study Hit paper breakdown → | 2013 | 827 |
| 5 | Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial Hit paper breakdown → | 2009 | 498 |
| 6 | Cytoreductive Nephrectomy in Patients with Synchronous Metastases from Renal Cell Carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium Hit paper breakdown → | 2014 | 359 |
| 7 | Randomized Phase III Trial of Temsirolimus Versus Sorafenib As Second-Line Therapy After Sunitinib in Patients With Metastatic Renal Cell Carcinoma Hit paper breakdown → | 2013 | 334 |
| 8 | 2001 | 333 | |
| 9 | The International Metastatic Renal Cell Carcinoma Database Consortium model as a prognostic tool in patients with metastatic renal cell carcinoma previously treated with first-line targeted therapy: a population-based study Hit paper breakdown → | 2015 | 320 |
| 10 | 2014 | 226 | |
| 11 | Open-Label, Single-Arm, Phase II Study of Pembrolizumab Monotherapy as First-Line Therapy in Patients With Advanced Non–Clear Cell Renal Cell Carcinoma Hit paper breakdown → | 2021 | 224 |
| 12 | A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial Hit paper breakdown → | 2021 | 218 |
| 13 | 2013 | 214 | |
| 14 | Evaluation of Clear Cell, Papillary, and Chromophobe Renal Cell Carcinoma Metastasis Sites and Association With Survival Hit paper breakdown → | 2021 | 211 |
| 15 | 2009 | 204 | |
| 16 | 2013 | 196 | |
| 17 | 2006 | 184 | |
| 18 | 2016 | 184 | |
| 19 | 2011 | 173 | |
| 20 | 1999 | 161 |
About Georg Arnold Bjarnason
Georg Arnold Bjarnason is a scholar working on Pulmonary and Respiratory Medicine, Oncology, Endocrine and Autonomic Systems, Cancer Research and Molecular Biology, having authored 214 papers that have together received 16.5k indexed citations. Recurring topics across this work include Renal cell carcinoma treatment (125 papers), Renal and related cancers (29 papers), Circadian rhythm and melatonin (19 papers), Cancer Genomics and Diagnostics (13 papers), Pancreatic and Hepatic Oncology Research (12 papers), Economic and Financial Impacts of Cancer (9 papers), Cancer Treatment and Pharmacology (6 papers) and Colorectal Cancer Treatments and Studies (6 papers). The work is most often cited by research in Pulmonary and Respiratory Medicine (8.6k citations), Cancer Research (3.6k citations), Endocrine and Autonomic Systems (1.4k citations), Oncology (3.6k citations) and Aging (191 citations). Georg Arnold Bjarnason has collaborated with scholars based in Canada, United States and Denmark. Frequent co-authors include Christina R. Lee, Robert S. Kerbel, John M.L. Ebos, James G. Christensen, William Cruz‐Muñoz, Frede N. Donskov, Richard C. Jordan, Toni K. Choueiri, Daniel Y.C. Heng and Lori Anne Wood. Their work appears in journals such as Journal of Clinical Oncology, Clinical Genitourinary Cancer, Annals of Oncology, European Urology and European Journal of Cancer.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.